Key Findings
- Overall 12% reduction in acute respiratory infection risk with vitamin D supplementation (OR 0.88, 95% CI: 0.81-0.96)
- Deficient participants (25(OH)D < 25 nmol/L) saw a 42% risk reduction — the strongest subgroup effect
- Daily or weekly dosing was significantly more protective than large bolus doses given monthly or quarterly
- Vitamin D upregulated cathelicidin and beta-defensin antimicrobial peptide expression in multiple trials
- No significant benefit was observed for participants with baseline serum 25(OH)D above 50 nmol/L